Umifenovir treatment is not associated with improved outcomes in
patients with coronavirus disease 2019: a retrospective study

https://doi.org/10.1016/j.cmi.2020.04.026

In a retrospective study, 81 COVID-19 patients were included, with 45 in the umifenovir group and 36 in the control group. Baseline clinical and laboratory characteristics were comparable between the two groups.
Thirty-three out of 45 (73%) patients in the umifenovir group tested negative for SARS-CoV-2 within 7 days after admission, the number was 28/36 (78%) in the control group (p 0.19). The median time from onset of symptoms to SARS-CoV-2 turning negative was 18 days  in the umifenovir group and 16 days  in the control group (p 0.42). No deaths or severe adverse reactions were found in both groups. This retrospective study found that umifenovir treatment did not shorten the negativity time of SARS-CoV-2, or the length of hospital stay in non-ICU hospitalized patients with COVID-19. No severe side effects were found in umifenovir treatment.

Tags: ,